Abstract
The serine/threonine protein kinase calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) plays critical roles in a range of biological processes. Despite its importance, only a handful of inhibitors of CAMKK2 have been disclosed. Having a selective small molecule tool to interrogate this kinase will help demonstrate that CAMKK2 inhibition can be therapeutically beneficial. Herein, we disclose SGC-CAMKK2-1, a selective chemical probe that targets CAMKK2.
Funder
National Institutes of Health
NIH Illuminating the Druggable Genome program
Mike Slive Foundation for Prostate Cancer Research
FAPESP
CNPq
AbbVie
Bayer Pharma AG
Boehringer Ingelheim
Canada Foundation for Innovation
Eshelman Institute for Innovation
Genome Canada
Innovative Medicines Initiative
Janssen
Merck KGaA Darmstadt Germany
MSD
Novartis Pharma AG
Ontario Ministry of Economic Development and Innovation
Pfizer
Takeda
Wellcome Trust
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献